The American journal of managed care
-
The annual special issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care® (AJMC), features coverage of the 2022 Annual Meeting of the American Society of Clinical Oncology, held June 3-7, 2022, in Chicago, Illinois. Clinical trials presented during the meeting and summarized in the issue include DESTINY-Breast04, DETERMINATION, SHINE, and ECHELON-1. ⋯ A final section features clinical findings presented by scientists affiliated with Strategic Alliance Partners of AJMC. Each issue section includes an interview with a key opinion leader participating in the meeting.
-
To examine the relationship between care experiences and inpatient opioid receipt during and after delivery for women hospitalized for vaginal delivery (VD). ⋯ Receipt of opioids may not be a significant determinant of the pain-specific patient care experiences of women hospitalized for VD.
-
In this time of aging and increasingly multimorbid populations, effective and efficient case management approaches play a crucial role in supporting patients who are navigating complex health care systems. Until now, no rigorous systematic review has synthesized studies about the cost-effectiveness of case management. ⋯ Existing studies often have adequate quality and, in many cases, show cost-effective or even cost-saving results. Case management appears to be a promising method to support patients facing complex care situations. However, variation among case management approaches is very high, and the topic needs further study to determine the most cost-effective way of providing such care coordination.
-
To assess provider and patient preferences for an oncologist selection tool, value-based care, involvement in cancer care, and end-of-life planning. ⋯ These results present a compelling rationale for developing a data-driven oncologist selection tool, optimizing patient and provider involvement in care, and expanding the portion of patients who have an advance directive at the start of their cancer care to optimize their cancer journey.
-
Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain. We projected US biosimilar savings from 2021 to 2025 under different scenarios. ⋯ Biosimilar savings from 2021 to 2025 were $38.4 billion under our main assumptions. Greater savings may be feasible if managed care and other settings increase biosimilar utilization and promote competition.